Investors finally found a reason to stop selling stocks, and the interesting part is where they chose to put the money. The S&P 500 rose 0.21% after a three-day losing streak, but the session didn’t revolve around a broad rush back into the same technology favorites. The bond market supplied relief, then health care and company-specific proof did most of the talking.
Treasury yields eased after the Treasury Department said it planned to increase buybacks of long-dated government debt by at least double, according to Alain Guillot’s market recap. That matters because lower yields can make future corporate profits look more valuable today. They also reduce the appeal of sitting in government bonds instead of owning stocks. The 10-year Treasury yield finished at 4.653%, enough of a drop to help sentiment without creating a full market reset.
The rate relief went elsewhere
The usual pattern would have been simple: yields fall, expensive growth stocks breathe easier, technology leads. Yesterday didn’t follow that script. Technology was the weakest major sector, down 1.07%, while health care jumped 3.51%. That gap is the session’s useful clue. Investors accepted the lower-rate argument, then applied it selectively.
There’s a mechanical reason that selectivity matters. When a rally leans on lower yields alone, the biggest beneficiaries are often the companies whose cash flows sit far in the future. When investors also demand fresh evidence, the money goes to businesses that can change their expected earnings power right now. Clinical trial readouts, improved profit margins and credible guidance can do that in a way a slight move in bonds can’t.
Health care has also been building its own momentum, with the sector up 10.19% over the last 20 sessions. That makes yesterday look like an acceleration of an existing preference rather than a one-day detour. In plain English, investors have been rewarding areas where the story is being updated by real data, and they’re becoming less forgiving toward technology names that already carry a lot of future optimism.
Proof beat popularity
Moderna gave the market the clearest example. The stock rose 176.63% after Moderna and Merck reported that a personalized mRNA cancer vaccine met primary and secondary endpoints in a Phase 3 melanoma trial when combined with Keytruda. That’s the kind of event that can change how investors value a drug pipeline almost overnight. It also changes the narrative around Moderna from a company still tied to its pandemic windfall to one with a more serious oncology case.
Humacyte and Tempus AI reinforced the same idea from different angles. Humacyte’s late-stage hemodialysis access trial success gave investors a clinical validation story. Tempus AI reported its first GAAP profit and raised its revenue outlook, turning a data and diagnostics narrative into a more measurable profit story. The common thread is evidence. In a market that has already paid dearly for future growth, yesterday’s biggest rewards went to companies that delivered something investors could underwrite now.
The losers showed the other side of that discipline. La-Z-Boy fell after earnings and its next-quarter sales outlook missed expectations. Nebius dropped after announcing a large convertible note plan, which can make investors think about future dilution. Seagate and FormFactor, both tied to the technology spending complex, slid as investors questioned how much good news was already reflected in their prices. The market wasn’t rejecting growth. It was asking growth stocks to earn their valuations again.
The morning is testing the chase
This morning’s setup keeps that argument alive. Futures are little changed overall, while the premarket mover list shows investors poking back into some speculative and technology-linked names. MicroStrategy and Coinbase are higher before the open, which points to renewed interest in crypto-sensitive stocks. Seagate and FormFactor are also trying to recover part of yesterday’s losses.
Moderna is the important counterweight, indicated down 12.47% before the open after its huge move. That pullback doesn’t erase the trial result. It shows how quickly investors move from discovery to price discipline once a stock has been dramatically revalued. The same market that paid up for evidence yesterday is already asking what the right price should be today.
The clean read is that lower yields helped stabilize the market, but they didn’t make investors careless. They used the relief to rotate, separate proof from promise, and mark down areas where enthusiasm had run ahead of fresh facts. That’s a healthier kind of skepticism than a blanket selloff, and it makes today’s open a test of whether evidence can keep beating habit.